Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study

Eli Lilly (LLY) announced results from the phase III EMBER-3 study, which showed that treatment with its orally administered investigational drug imlunestrant significantly reduced the risk of disease progression or death in certain patients with advanced breast cancer (ABC).The EMBER-3 study enrolled patients with estrogen receptor (ER)-positive, HER2-negative ABC whose disease progressed during or following an aromatase inhibitor (AI) therapy, with or without a CDK 4/6 inhibitor. These patients were then ...